| Literature DB >> 34422271 |
Tadele Mekuriya Yadesa1,2, Freddy Eric Kitutu3, Serawit Deyno1,4, Patrick Engeu Ogwang1, Robert Tamukong1, Paul E Alele5.
Abstract
BACKGROUND: Occurrence of adverse drug reactions is a major global health problem mostly affecting older adults. Identifying the magnitude and predictors of adverse drug reactions is crucial to developing strategies to mitigate the burden of adverse drug reactions. This study's objectives were to estimate and compare the prevalences of adverse drug reactions, to characterize them and to identify the predictors among hospitalized older adults.Entities:
Keywords: Prevalence; adverse drug reactions; hospitalized; older adults; predictors
Year: 2021 PMID: 34422271 PMCID: PMC8377309 DOI: 10.1177/20503121211039099
Source DB: PubMed Journal: SAGE Open Med ISSN: 2050-3121
Figure 1.Flow chart showing included and excluded studies.
Summary of the included studies.
| Income status (no. of ADRs) | Study | Patients’ country | Study design | Setting | ADR definition | ADR causality method | Total participants | % of females (52.2%) | Mean age (media | Frequency (prevalence, %) of ADR |
|---|---|---|---|---|---|---|---|---|---|---|
| HICs ( | Sikdar et al.[ | Canada | Retrospective cohort | Acute care | Edwards and Aronson | E and Y code | 64,446 | 52 | NR | 4858(6) |
| Onder et al.[ | Italy | Retrospective cross-sectional | General wards | WHO | Naranjo | 5936 |
| 78 | 383(6.5) | |
| Tangiisuran et al.[ | UK | Prospective cohort | Geriatric and stroke wards | Edwards and Aronson | Howard | 690 | 61 | 85 | 95(12.5) | |
| Tangiisuran et al.[ | UK | Prospective cross-sectional | Geriatric ward | Edwards and Aronson | Hallas et al. | 560 | 63 | 87 | 83(13) | |
| Kojima et al.[ | Japan | Retrospective cohort | Geriatric ward | Nebeker et al. | Geriatrician’s diagnosis | 1155 | 53 | 83 | 178(15) | |
| O’Mahony et al.[ | Ireland | Retrospective cohort | General wards | WHO | WHO–UMC | 2217 | 56 | 78 | 467(21) | |
| Lavan et al.[ | Europe | Prospective cohort | Emergency ward | WHO | WHO–UMC | 644 | 51.6 | 77.8 | 139(21.6) | |
| Conforti et al.[ | Italy | Prospective cross-sectional | Geriatric ward | WHO | WHO–UMC | 102 | 50.8 | 81.9 | 256(25) | |
| Dormann et al.[ | Germany | Prospective cohort | General wards | WHO | Naranjo | 158 | 0 | 74 | 78(25.9) | |
| O’Connor et al.[ | Ireland | Prospective cohort | General wards | WHO | WHO–UMC | 513 | 56 | 79 | 178(26) | |
| Alhawassi et al.[ | Australia | Retrospective cross-sectional | Acute care | WHO | Naranjo | 503 |
| 80 | 132(26.2) | |
| De Paepe et al.[ | Belgium | Prospective cross-sectional | Emergency ward | Edwards and Aronson | Naranjo | 80 | 54 | 76 | 87(46) | |
| LMICs (n = 818 ADRs) | Ahmed et al.[ | Pakistan | Prospective cohort | General wards | WHO | WHO–UMC | 1000 | 51.5 | 70 | 107(10.7) |
| Galli et al.[ | Brazil | Retrospective cross-sectional | ICU | WHO | Naranjo | 185 | 45 | 71 | 49(18) | |
| Rawat[ | India | Prospective cross-sectional | General wards | WHO | Naranjo | 112 | 40 | 68 | 31(27) | |
| Najjar et al.[ | Malaysia | Prospective cohort | General wards | WHO | Naranjo | 400 | 54 | 74 | 118(30) | |
| Harugeri et al.[ | India | Prospective cross-sectional | General wards | WHO | WHO–UMC and Naranjo | 920 | 41 | 66 | 419(32) | |
| Sneha et al.[ | India | Prospective cross-sectional | General wards | WHO | Naranjo | 153 | 73 | 63 | 94(64) |
ADRs: adverse drug reactions; WHO: World Health Organization; UK: United Kingdom; WHO-UMC: World Health Organization Uppsala Monitoring Center; ICU: intensive care unit.
Value not reported.
General wards: Medical, surgical, oncology, nephrology and stroke wards.
The characteristics of ADRs documented among the hospitalized older adults.
| Income status (n of ADRs) | Study | Total ADRs | Type of ADR ( | Causality of ADR ( | Preventability of ADR ( | Severity of ADR ( | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Type A ADR | Type B ADR | Possible ADR n(%) | Probable ADR n(%) | Definite ADR | Preventable ADR n(%) | Non-preventable ADR | Severe ADR | Mild to moderate ADR | |||
| HICs ( | Dormann et al.[ | 78 |
|
| 22(28) | 52(67) | 4(5) | 46(68) | 24(32) | 7(9) | 68(91) |
| Onder et al.[ | 383 |
|
|
|
|
|
|
| 221(58) | 162(42) | |
| O’Connor et al.[ | 178 |
|
| 9(5) | 117(66) | 52(29) |
|
| 57(32) | 121(68) | |
| Tangiisuran et al.[ | 83 | 78(94) | 5(6) | 23(28) | 41(49) | 19(23) | 52(63) | 31(37) | 60(72) | 23(28) | |
| Conforti et al.[ | 256 |
|
|
|
|
|
|
| 137(54) | 119(46) | |
| De Paepe et al.[ | 87 |
|
| 24(28) | 62(71) | 1(1) | 70(80) | 17(20) |
|
| |
| Tangiisuran et al.[ | 95 |
|
| 25(26) | 47(49) | 23(24) |
|
|
|
| |
| Alhawassi et al.[ | 132 |
|
| 25(19) | 101(76.5) | 6(4.5) | 86(65) | 46(35) | 42(32) | 90(68) | |
| LMICs ( | Najjar et al.[ | 118 | 86(73) | 32(27) | 41(35) | 73(62) | 5(4) | 86(73) | 32(27) | 16(14) | 102(86) |
| Harugeri et al.[ | 419 | 386(92) | 33(8) | 112(27) | 302(72) | 5(1) | 203(48) | 216(52) | 4(1) | 415(99) | |
| Sneha et al.[ | 94 |
|
|
|
|
|
|
| 0 | 94(100) | |
| Total | 1923 | 550(89) | 70(11) | 281(23) | 795(67) | 115(10) | 543(60) | 366(40) | 544(31) | 1194(69) | |
ADR: adverse drug reactions.
Values not reported.
The comparison of prevalence, percentage of preventable and severe ADRs among hospitalized older adults from LMICs and HICs.
| Income status | Prevalence of ADRs | Percentage of severe ADRs | Percentage of preventable ADRs | |||
|---|---|---|---|---|---|---|
| HICs ( | LMICs ( | HICs (n = 4) | LMICs ( | HICs ( | LMICs ( | |
| Lowest percentage | 6 | 10.7 | 8.9 | 0 | 63 | 48 |
| Highest percentage | 46 | 64 | 72 | 14 | 80 | 73 |
| Mean (95% CI) | 20.5 (14.8, 27.3) | 30.2 (17.8, 46.1) | 42.7(25.5, 58.4) | 5(0, 14) | 68.4(63.7, 76.4) | 60.5(48, 73) |
CI: confidence intervals.
Figure 2.Forest plot of prevalence of ADR by study by income status.
Figure 3.Forest plot of prevalence of ADR by study design.
Figure 4.Forest plot of prevalence of ADR by study setting.
Figure 5.Risk of bias graph: review authors’ judgments about each risk of bias item presented as percentages across all included studies.
Figure 6.Funnel plot of Egger’s test (p value < 0.0001).
The independent risk factors identified among the hospitalized older adults.
| Categories of the risk factors | Specific predicting risk factors |
|---|---|
| Patient factors | Age[ |
| Disease factors | Hyperlipidemia[ |
| Medication factors | PIM[ |
| Health facility factors | Ward or setting[ |
ADR: adverse drug reactions; CCI: Charlson comorbidity index; STOPP: Screening Tool of Older Persons’ Prescriptions.
Age ⩾70, or ⩾75 or ⩾80 or ⩾85 years.
Varied from mild renal insufficiency to renal failure.
STOPP criteria used to classify drugs.
Included insulin and oral antidiabetics.
Nursing homes.